Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
V.ARCH
Alternate Symbol(s):
ACHFF
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is...
LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(229)
•••
Viking2233
X
Post by
Viking2233
on Dec 04, 2024 12:10pm
My Concerns…..
Well another week has passed and more patients dosed but I do have concerns, not with the science, not with the drug, not with trials but with the lack of communication and the hoops a company has to
...more
(229)
•••
Viking2233
X
Post by
Viking2233
on Nov 24, 2024 3:41pm
Silence Continues ………
But so does the nefarious shorting algorithms! In my humble opinion the lack of communication and updates, just plays into the hands of those shorting. I
...more
(229)
•••
Viking2233
X
Post by
Viking2233
on Nov 17, 2024 5:28pm
Nothing but Silence
Arch update Well I wish I had something positive to report. I only have my observations and opinions. We are 9 months into dosing in Turkey at 5 sites. Arch management reluctant
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 11, 2024 7:30am
New Press Release - Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in Canada for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...
read article.
(229)
•••
Viking2233
X
Comment by
Viking2233
on Oct 31, 2024 9:23pm
RE:Top 10 Undervalued Healthcare Sector Stocks
Thanks for this River, I have been saying this for months. We are ready to launch, glad I am not yhe only one who can see this!
(9)
•••
Riverfolk
X
Post by
Riverfolk
on Oct 31, 2024 6:25pm
Top 10 Undervalued Healthcare Sector Stocks
Globe and Mail Article
(229)
•••
Viking2233
X
Post by
Viking2233
on Oct 29, 2024 3:18pm
Connecting the dots
1. Been dosing at 5 Turkish sites for 9 months now. Silence from management but no news in this case could be great news as no adverse reactions reported. 2. How many patients dosed? Nobody
...more
(229)
•••
Viking2233
X
Post by
Viking2233
on Oct 27, 2024 7:57pm
Stockholm Conference
Some interesting facts for consideration. The Stockholm conference runs from November 4 to 13. This is a 9 day conference that we are presenting at. I wonder who we are sending and how many days will
...more
(229)
•••
Viking2233
X
Post by
Viking2233
on Oct 23, 2024 12:11pm
California Conference
Well today marks conference number 1 that Arch is attending. I errored in my previous post stating they were presenting, in fact they are simply attending but hopefully networking aggressively. That
...more
(229)
•••
Viking2233
X
Post by
Viking2233
on Oct 17, 2024 6:33am
Is the end of trial near…..
Arch manangement announced on X yesterday that it will be presenting at 2 conferences starting Oct 23 in San Diego California and in November in Stockholm Sweden. Now one thing we know is Arch CEO is
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 15, 2024 6:23pm
New Press Release - Arch Biopartners Arranges Non-Brokered Private Placement
TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement offering of 290,323 common shares priced at $1.55 per common share (the “Common Shares”) for gross...
read article.
(229)
•••
Viking2233
X
Post by
Viking2233
on Oct 14, 2024 7:51pm
5 Turkish Sites Dosing
At some point and time the markets will finally wake up and realize that Arch has been dosing at 5 sites for almost 8 months. We have no idea how many patients have been dosed but we know that there
...more
(229)
•••
Viking2233
X
Post by
Viking2233
on Oct 06, 2024 5:21pm
7 Months …..
How long does it take in Canada to get ethics approval and provincial approval for drug trial????? We have FDA and Health Canada approval plus we have been dosing in Turkey at 5 sites with no adverse
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 03, 2024 7:45am
New Press Release - Closes Units for Debt Settlement
TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that was previously announced on September 26, 2024 to settle an aggregate total of $2,600,000 of principal...
read article.
(229)
•••
Viking2233
X
Post by
Viking2233
on Sep 28, 2024 11:18am
Algo’s taking a break
Nice to see share price finally moving in the right direction. It's simply amazing how the share price reacts when the shorts take a pause. We are almost 8 months into dosing at 5 sites in Turkey
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing